Mark A. Glickman is listed as an executive officer and director on 3 SEC Form D filings by 2 issuers between Feb 2016 and May 2025: Aralez Pharmaceuticals Inc. (Vancouver, British Columbia, Canada (as filed: A1) — pharmaceuticals — 2016; $75M reported sold to 3 investors) and MetaVia Inc. (Cambridge, MA — biotechnology — 2024–2025; $17M reported sold to 59 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director, over about 9 years. Across those companies the filings report $92M sold in total.
Listed alongside Andrew I. Koven (3 shared filings), D. Gordon Strickland (2 shared filings), Hyung Heon Kim (2 shared filings), James P. Tursi (2 shared filings), Jason Groves (2 shared filings) and 14 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Mark. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — 2 bankruptcy cases matching the name listed in Key records below.
What this means 2 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 3 public filings for Mark A. Glickman and found 2 differences: Same name, different state: "Mark Glickman" (FL) is a separate record; Mark A. Glickman is listed with 2 different address states: A1, MA.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.